Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510697 | 1.00 | ADRB2 (0.43) | ADRB2ADRB1TRPV3NOTUMFAAH | |
| SCHEMBL8511122 | 0.87 | IDO1 (0.45) | ADRB2ADRB1NOTUM | |
| SCHEMBL8511124 | 0.87 | IDO1 (0.45) | ADRB2ADRB1NOTUM | |
| SCHEMBL14981124 | 0.83 | ANPEP (0.38) | ADRB2ADRB1NOTUMFAAHPDE2A | |
| SCHEMBL15157681 | 0.83 | SLC6A4 (0.40) | ADRB2ADRB1NOTUMFAAHPDE2A | |
| Hydrochloric Acid SCHEMBL15157818 | 0.82 | AKR1C3 (0.39) | ADRB2ADRB1FAAHPDE2ADAO | |
| Hydrochloric Acid SCHEMBL28117600 | 0.82 | AKR1C3 (0.39) | ADRB2ADRB1FAAHPDE2ADAO | |
| SCHEMBL9570842 | 0.80 | ADRB2 (0.40) | ADRB2ADRB1TRPV3NOTUMFAAH | |
| SCHEMBL297668 | 0.78 | SLC6A2 (0.45) | KMO | |
| SCHEMBL12497722 | 0.78 | SLC6A2 (0.45) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | ADRB2 1632/4885ADRB1 2033/4885TRPV3 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.